This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator.
Ayurvedic medicines, though widely marketed across Western countries as food supplements, herbal remedies, or traditional health products, are not recognized as licensed pharmaceuticals requiring premarket efficacy disclosure.1 Their legal entry is facilitated through frameworks such as the U.S. Dietary Supplement Health and Education Act (DSHEA), the EU Traditional Herbal Medicinal Products Directive (THMPD), Canada’s Natural Health Products Regulations, and Australia’s complementary medicine listing system.1,2 Despite bypassing premarket drug approval, these products remain under postmarket pharmacovigilance surveillance.1,3 Healthcare providers are obliged to document usage and report adverse reactions to national pharmacovigilance agencies, which collate, analyze, and establish causality using World Health Organization–Uppsala Monitoring Centre (WHO-UMC) criteria.3 Scientific literature has documented major adverse reactions to Ayurvedic supplements, including hepatotoxicity (Tinospora cordifolia, Ashwagandha, Turmeric, Psoralea corylifolia), hypersensitivity reactions, and heavy-metal poisoning (lead, mercury, arsenic).4-6 Case reports from the United States, United Kingdom, and India substantiate these risks, with outcomes ranging from acute liver failure to Cushing’s syndrome due to steroid adulteration.4,7 Indian statutory bodies—including the Ministry of AYUSH, CDSCO, ICMR, and NCISM— have acknowledged these concerns, establishing the Ayush Pharmacovigilance Program of India (APvPI) and issuing guidelines for adverse drug reaction reporting.3,8 This deliberation highlights the tension between traditional use and modern regulatory safeguards, underscoring the need for harmonized global vigilance, transparent labeling, and evidence-based integration of Ayurvedic medicines into healthcare systems.1,8
Shri Gopal Kabra. Ayurvedic Medicines in Global Markets: Legal Provisions, Pharmacovigilance, and Adverse Reactions. Ind J Anct Med Yoga. 2026; 19(4): 249-255.
This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator.
| Received | Accepted | Published |
|---|---|---|
| September 01, 2026 | October 03, 2026 | December 30, 2026 |
Sunday 22 November 2026, 04:40:54 (IST)
Download citation
Highlight selected keywords in the article text.
| Received | September 01, 2026 |
| Accepted | October 03, 2026 |
| Published | December 30, 2026 |
This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator.